Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cell Genesys
Cohorts of three to six patients will be assigned to receive intravesical (into the bladder) administration of CG0070 either Weekly or Every 4 Weeks for up to a total of 6 doses.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
High grade non-muscle invasive bladder cancer (stages Ta, T1 and/or CIS - carcinoma in situ). High grade being defined as G2 or G3 disease.
Failure of at least one prior treatment with BCG, defined as evidence of TCC on cystoscopic exam and biopsy or cystoscopic exam and urine cytology at least 6 weeks from last BCG treatment
ECOG performance status 0-1
Adequate bone marrow, renal, liver and coagulation function
You may not be if
Pregnant or nursing
HIV positive
Use of anticoagulants such as coumadin or heparin
History of bleeding disorder
Active systemic autoimmune disease or chronic immunodeficiency
